NCT06594640View on ClinicalTrials.gov

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

July 30, 2027

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Mitoxantrone Hydrochloride Liposome

assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2

DRUG

Rituximab (R)

375mg/m2, D2

DRUG

Cyclophosphamide (CTX)

750mg/m2, D2

DRUG

Vincristin

1.2mg/m2, maximum 2mg， D2

DRUG

Prednisolone

60mg/m2, D2-6

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Disease Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER